Tumor antigens and tumor vaccines: Peptides as immunogens

Seminars in Surgical Oncology

Volumn 12, Issue 6, 1996, Pages 446-453

  Slingluff Jr , Craig L ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

cultured tumor cells; cytotoxic T lymphocytes; immunologic adjuvants; immunotherapy; melanoma; molecular sequence data; neoplasm antigens; peptides immunology; tumor infiltrating lymphocytes

Indexed keywords

CANCER VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 12; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PEPTIDE; TUMOR ANTIGEN;

ANTIGEN DETECTION; ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CYTOTOXIC T LYMPHOCYTE; EPITOPE MAPPING; HUMAN; MELANOMA; PRIORITY JOURNAL; REVIEW; TUMOR ASSOCIATED LEUKOCYTE; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CLINICAL TRIALS; CYTOTOXICITY, IMMUNOLOGIC; EPITOPES; HUMANS; IMMUNOTHERAPY; LYMPHOCYTES; MAJOR HISTOCOMPATIBILITY COMPLEX; MELANOMA; ONCOGENES; PEPTIDES; VACCINES, SYNTHETIC;

EID: 10344242384     PISSN: 87560437     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2388(199611/12)12:6<446::AID-SSU10>3.0.CO;2-T     Document Type: Review

References (89)

1. Gross L: Intradermal immunization of C3H mice against a sarcoma that originated in an animal of the same line. Cancer Res 3:326-333, 1943.
2. Rosenberg SA, Yannelli JR, Yang JC, et al: Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 86:1159-1166, 1994.
3. Townsend A, Bodmer H: Antigen recognition by class I-restricted T lymphocytes. Annu Rev Immunol 7:601-624, 1989.
4. Lethe B, van den Eynde B, van Pel A, et al: Mouse tumor rejection antigens P815A and P815B: Two epitopes carried by a single peptide. Eur J Immunol 22:2283-2288, 1992.
5. Van den Eynde B, Lethe B, Van Pel A, et al: The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice. J Exp Med 173:1373-1384, 1991.
6. Wolfel T, Klehmann E, Muller C, et al: Lysis of human melanoma cells by autologous cytolytizc T cell clones. Identification of human histocompatibility leukocyte antigen A2 as a restriction element for three different antigens. J Exp Med 170:797-810, 1989.
7. Darrow TL, Slingluff CL Jr, Seigler HF: The role of HLA class I antigens in recognition of melanoma cells by tumor-specific cytotoxic T lymphocytes. Evidence for shared tumor antigens. J Immunol 142:3329-3335, 1989.
8. Horn SS, Topalian SL, Simonis T, et al: Common expression of melanoma tumor-associated antigens recognized by human tumor infiltrating lymphocytes: Analysis by human lymphocyte antigen restriction. J Immunother 10:153-164, 1991.
9. Slovin SF, Lackman RD, Ferrone S, et al: Cellular immune response to human sarcomas: Cytotoxic T cell clones reactive with autologous sarcomas. I. Development, phenotype, and specificity. J Immunol 137:3042-3048, 1986.
10. Ioannides CG, Freedman RS, Platsoucas CD, et al: Cytotoxic T cell clones isolated from ovarian tumor-infiltrating lymphocytes recognize multiple antigenic epitopes on autologous tumor cells. J Immunol 146:1700-1707, 1991.
11. Ioannides CG, Fisk B, Pollack MS, et al: Cytotoxic T-cell clones isolated from ovarian tumor-infiltrating lymphocytes recognize common determinants on non-ovarian tumour clones. Scand J Immunol 37:413-424, 1993.
12. Peoples GE, Schoof DD, Andrews JV, et al: T-cell recognition of ovarian cancer. Surgery 114:227-234, 1993.
13. Peoples GE, Goedegebuure PS, Andrews JV, et al: HLA-A2 presents shared tumor-associated antigens derived from endogenous proteins in ovarian cancer. J Immunol 151:5481-5491, 1993.
14. Schwartzentruber DJ, Solomon D, Rosenberg SA, Topalian SL: Characterization of lymphocytes infiltrating human breast cancer: Specific immune reactivity detected by measuring cytokine secretion. J Immunother 12:1-12, 1992.
15. Lind DS, Tuttle TM, Bethke KP, et al: Expansion and tumour specific cytokine secretion of bryostatin-activated T-cells from cryopreserved axillary lymph nodes of breast cancer patients. Surg Oncol 2:273-282, 1993.
16. Horn SS, Rosenberg SA, Topalian SL: Specific immune recognition of autologous tumor by lymphocytes infiltrating colon carcinomas: Analysis by cytokine secretion. Cancer Immunol Immunother 36:1-8, 1993.
17. Tsang KY, Zaremba S, Nieroda CA, et al: Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J Natl Cancer Inst 87:982-990, 1995.
18. Skipper JC, Hendrickson RC, Gulden PH, et al: An HLA-A2-restricted tyrosinase antigen on melanoma cells results from post-translational modification and suggests a novel pathway for processing of membrane proteins. J Exp Med 183:527-534, 1996.
19. Wolfel T, Van Pel A, Brichard V. et al: Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur J Immunol 24:759-764, 1994.
20. Kang X, Kawakami Y, el-Gamil M, et al: Identification of a tyrosinase epitope recognized by HLA-A24-restricted, tumor-infiltating lymphocytes. J Immunol 155:1343-1348, 1995.
21. Brichard VG, Herman J, Van Pel A, et al: A tyrosinase nonapeptide presented by HLA-B44 is recognized on a human melanoma by autologous cytolytic T lymphocytes. Eur J Immunol 26:224-230, 1996.
22. Cox AL, Skipper J, Chen Y, et al: Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 264:716-719, 1994.
23. Bakker AB, Schreurs MW, Tafazzul G, et al: Identification of a novel peptide derived from the melanocyte-specific gp100 antigen as the dominant epitope recognized by an HLA-A2. I-restricted anti-melanoma CTL line. Int J Cancer 62:97-102, 1995.
24. Kawakami Y, Eliyahu S, Jennings C, et al: Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol 154:3961-3968, 1995.
25. Bakker AB, Schreurs MW, de Boer AJ, et al: Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J Exp Med 179:1005-1009, 1994.
26. Kawakami Y, Eliyahu S, Delgado CH, et al: Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA 91:6458-6462, 1994.
27. Skipper JC, Kittlesen DJ, Hendrikson RC, et al: Shared epitopes for HLA-A3 restricted melanoma-reactive human CTL include a naturally processed epitope from Pmel-17/gp 100. J Immunol (in press).
28. Coulie PG, Brichard V, Van Pel A, et al: A new gene encoding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 180:35-42, 1994.
29. Kawakami Y, Eliyahu S, Sakaguchi K, et al: Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med 180:347-352, 1994.
30. Castelli C, Storkus WJ, Maeurer MJ, et al: Mass spectrometric identification of a naturally processed melanoma peptide recognized by CDS+ cytotoxic T lymphocytes. J Exp Med 181:363-368, 1995.
31. Wang RF, Robbins PF, Kawakami Y, et al: Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes [published erratum appears in J Exp Med 181:1261, 1995]. J Exp Med 181:799-804, 1995.
32. Traversari C, van der Bruggen P, Luescher IF, et al: A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen M22-E. J Exp Med 176:1453-1457, 1992.
33. van der Bruggen P, Szikora JP, Boel P, et al: Autologous cytolytic T lymphocytes recognize a MAGE-1 nonapeptide on melanomas expressing HLA-Cw * 1601. Eur J Immunol 24:2134-2140, 1994.
34. Celis E, Tsai V, Crimi C, et al: Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. Proc Natl Acad Sci USA 91:2105-2109, 1994.
35. Gaugler B, Van den Eynde B, van der Bruggen P, et al: Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med 179:921-930, 1994.
36. van der Bruggen P, Bastin J, Gajewski T, et al: A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur J Immunol 24:3038-3043, 1994.
37. Boel P, Wildmann C, Sensi ML, et al: BAGE: A new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity 2:167-175, 1995.
38. Van den Eynde B, Peeters O, De Backer O, et al: A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J Exp Med 182:689-698, 1995.
39. Fisk B, Blevins TL, Wharton JT, Ioannides CG: Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med 181:2109-2117, 1995.
40. Lustgarten J, Sherman L: Generation of xenogeneic cytotoxic T cells from peptides derived from the her-2/neu protooncogene. In 9th International Congress of Immunology, July 27, 1995, 663, 1995 (Abstract 3935).
41. Yoshino I, Peoples GE, Goedegebuure PS, et al: Association of HER2/neu expression with sensitivity to tumor-specific CTL in human ovarian cancer. J Immunol 152:2393-2400, 1994.
42. Linehan DC, Peoples GE, Parikh AS, et al: Ovarian and breast tumor-associated T lymphocytes stimulated with an antigenic peptide derived from her2/neu show enhanced cytotoxicity against autologous tumor. Surg Forum 45:568-570, 1994.
43. Peoples GE, Goedegebuure PS, Smith R, et al: Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. Proc Natl Acad Sci USA 92:432-436, 1995.
44. Yoshino I, Goedegebuure PS, Peoples GE, et al: HER2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer. Cancer Res 54:3387-3390, 1994.
45. Robbins PF, el-Gamil M, Li YF, et al: Cloning of a new gene encoding an antigen recognized by melanoma-specific HLA-A24-restricted tumor-infiltrating lymphocytes. J Immunol 154:5944-5950, 1995.
46. Morioka N, Kikumoto Y, Hoon DS, et al: A decapeptide (Gln-Asp-Leu-Thr-Met-Lys-Tyr-Gln-Ile-Phe) from human melanoma is recognized by CTL in melanoma patients. J Immunol 153:5650-5658, 1994.
47. Coulie PG, Lehmann F, Lethe B, et al: A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc Natl Acad Sci USA 92:7976-7980, 1995.
48. Rosenberg SA: Cancer vaccines based on genes encoding cancer regression genes. Presentation at the Society for Biologic Therapy November 2, 1995, Williamsburg, VA.
49. Van den Eynde B, Gaugler B, van der Bruggen P, et al.: Human tumour antigens recognized by T-cells: Perspectives for new cancer vaccines. Biochem Soc Trans 23:681-686, 1995.
50. Engelhard VH: Structure of peptides associated with MHC class I molecules. Curr Opin Immunol 6:13-23, 1994.
51. Topalian SL: MHC class II restricted tumor antigens and the role of CD4+ T cells in cancer immunotherapy. Curr Opin Immunol 6: 741-745, 1994.
52. Engelhard VH: Structure of peptides associated with class I and class II MHC molecules. Annu Rev Immunol 12:181-207, 1994.
53. Topalian SL, Rivoltini L, Mancini M, et al: Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene. Proc Natl Acad Sci USA 91:9461-9465, 1994.
54. Chen Q, Hersey P: MHC-restricted responses of CD8+ and CD4+ T-cell clones from regional lymph nodes of melanoma patients. Int J Cancer 51:218-224, 1992.
55. Radrizzani M, Benedetti B, Castelli C, et al: Human allogeneic melanoma-reactive T-helper lymphocyte clones: Functional analysis of lymphocyte-melanoma interactions. Int J Cancer 49:823-830, 1991.
56. Takahashi T, Chapman PB, Yang SY, et al: Reactivity of autologous CD4+ T lymphocytes against human melanoma. Evidence for a shared melanoma antigen presented by HLA-DR15. J Immunol 154:772-779, 1995.
57. Disis ML, Calenoff E, McLaughlin G, et al: Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res 54:16-20, 1994.
58. Ransom JH, Pelle BA, Hubers H, et al: Identification of colon tumor-associated antigens by T-cell lines derived from tumor-infiltrating lymphocytes and peripheral-blood lymphocytes from patients immunized with an autologous tumor-cell/bacillus Calmette-Guerin vaccine. Int J Cancer 54:734-740, 1993.
59. Ioannides CG, Freedman RS: T cell responses to ovarian tumor vaccines: Identification and significance for future immunotherapy. Int Rev Immunol 7:349-364, 1991.
60. Qin H, Chen W, Takahashi M, et al: CD4+ T-cell immunity to mutated ras protein in pancreatic and colon cancer patients. Cancer Res 55:2984-2987, 1995.
61. Weidmann E, Logan TF, Yasumura S, et ai: Evidence for oligoclonal T-cell response in a metastasis of renal cell carcinoma responding to vaccination with autologous tumor cells and transfer of in vitro-sensitized vaccine-draining lymph node lymphocytes. Cancer Res 53:4745-4749, 1993.
62. Muul LM, Spiess PJ, Director EP, Rosenberg SA: Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma. J Immunol 138:989-995, 1987.
63. Luscher U, Filgueira L, Juretic A, et al: The pattern of cytokine gene expression in freshly excised human metastatic melanoma suggests a state of reversible energy of tumor-infiltrating lymphocytes. Int J Cancer 57:612-619, 1994.
64. Zuber M, Luscher U, Spagnoli GG, et al: Cytokine gene expression in metastatic melanoma. Surg Forum 45:519-521, 1994.
65. Vitolo D, Zerbe T, Kanbour A, et al: Expression of mRNA for cytokines in tumor-infiltrating mononuclear cells in ovarian adenocarcinoma and invasive breast cancer. Int J Cancer 51:573-580, 1992.
66. Mattei S, Colombo MP, Melani C, et al: Expression of cytokine/growth factors and their receptors in human melanoma and melanocytes. Int J Cancer 56:853-857, 1994.
67. Chen Q, Daniel V, Maher DW, Hersey P: Production of IL-10 by melanoma cells: Examination of its role in immunosuppression mediated by melanoma, Int J Cancer 56:755-760, 1994.
68. Bennicelli JL, Guerry D 4th: Production of multiple cytokines by cultured human melanomas. Exp Dermatol 2:186-190, 1993.
69. Cochran AJ, Pihl E, Wen DR, et al: Zoned immune suppression of lymph nodes draining malignant melanoma: Histologic and immunohistologic studies. J Natl Cancer Inst 78:399-405, 1987.
70. Hoon DS, Bowker RJ, Cochran AJ: Suppressor cell activity in melanoma-draining lymph nodes. Cancer Res 47:1529-1533, 1987.
71. Mukherji B, Wilhelm SA, Guha A, Ergin MT: Regulation of cellular immune response against autologous human melanoma. I. Evidence for cell-mediated suppression of in vitro cytotoxic immune response. J Immunol 136:1888-1892, 1986.
72. Mukherji B, Nashed AL, Guha A, Ergin MT: Regulation of cellular immune response against autologous human melanoma. II. Mechanism of induction and specificity of suppression. J Immunol 136:1893-1898, 1986.
73. Hersey P, Si Z, Smith MJ, Thomas WD: Expression of the costimulatory molecule B7 on melanoma cells, Int J Cancer 58:527-532, 1994.
74. Townsend SE, Allison JP: Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells [see comments]. Science 259:368-370, 1993.
75. Ridge JP, Fuchs EJ, Matzinger P: Neonatal tolerance revisited: Turning on newborn T cells with dendritic cells. Science 271: 1723-1726, 1996.
76. Celluzzi CM, Mayordomo JI, Storkus WJ, et al: Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J Exp Med 183:283-287, 1996.
77. Zitvogel L, Mayordomo JI, Tjandrawan T, et al: Therapy of murine tumors with tumor peptide-pulsed dendritic cells: Dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med 183:87-97, 1996.
78. Mayordomo JI, Zorina T, Storkus WJ, et al: Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nature Med 1:1297-1302, 1995.
79. Marchand M, Weynants P, Rankin E, et al: Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3, Int J Cancer 63:883-885, 1995.
80. Dranoff G, Jaffee E, Lazenby A, et al: Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 90:3539-3543, 1993.
81. Biron CA, Gazzinelli RT: Effects of IL-12 on immune responses to microbial infections: A key mediator in regulating disease outcome. Curr Opin Immunol 7:485-496, 1995.
82. Blieden TM, McAdam AJ, Frelinger JG, Lord EM: Mechanism of cytolytic T lymphocyte killing of a low class I-expressing tumor. J Immunol 147:1433-1438, 1991.
83. D'Alessandro G, Zardawi I, Grace J, et al: Immunohistological evaluation of MHC class I and II antigen expression on nevi and melanoma: Relation to biology of melanoma. Pathology 19:339-346, 1987.
84. Levitsky HI, Lazenby A, Hayashi RJ, Pardoll DM: In vivo priming of two distinct antitumor effector populations: The role of MHC class I expression. J Exp Med 179:1215-1224, 1994.
85. Vegh Z, Wang P, Vanky F, Klein E: Selectively down-regulated expression of major histocompatibility complex class I alleles in human solid tumors. Cancer Res 53 (10 Suppl):2416-2420, 1993.
86. Restifo NP, Esquivel F, Kawakami Y, et al: Identification of human cancers deficient in antigen processing. J Exp Med 177:265-272, 1993.
87. Traversari C, van der Bruggen P, Van den Eynde B, et al: Transfection and expression of a gene coding for a human melanoma antigen recognized by autologous cytolytic T lymphocytes. Immunogenetics 35:145-152, 1992.
88. Achilles E, Schroder S: [Positive cytokeratin results in malignant melanoma. Pitfall in differential immunohistologic diagnosis of occult neoplasms]. [German]. Pathologe 15:235-241, 1994.
89. Lehmann F, Marchand M, Hainaut P, et al: Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection. Eur J Immunol 25:340-347, 1995.